The Impact of Trump’s 100% Tariff on Indian Pharma: Limited at Best
Market Reaction vs. Ground Reality
The announcement of a 100% US tariff on branded and patented drug imports, effective October 1, 2025, triggered a sharp decline in some of India’s biggest pharmaceutical stocks such as Sun Pharma, Dr. Reddy’s Laboratories, and Cipla. However, the market reaction appears largely unfounded.
The tariffs primarily target branded, patented drugs rather than generic medicines, which form the bulk of India’s exports to the United States. According to ICICI Securities’ research analyst Pankaj Pandey, the near-term impact remains limited, though uncertainty lingers over whether complex generics and biosimilars might eventually come under the tariff umbrella.
India’s Share in US Pharma Imports
While the US is the largest export market for Indian drugmakers, India accounts for only 5.3% of total US pharma imports.
-
India’s pharma exports to the US in 2024: $13.1 billion (about one-third of total pharma exports in FY25).
-
Ireland was the top exporter with a 30% share, followed by Switzerland (8.8%) and Germany (7.8%).
-
India ranks in the top five but is far below Europe in terms of supplying branded finished drugs.
This discrepancy stems from India’s dominance in low-cost generics rather than high-value patented medicines, which are the main focus of Trump’s tariff.
Generic Exports: India’s Strength
In FY25, India’s generic exports to the US stood at $10.5 billion, accounting for 78% of its total pharma exports.
This dominance in generics shields India’s industry from the direct impact of the tariffs. Moreover, many Indian pharma firms have manufacturing subsidiaries within the US, ensuring that production and sales there are exempt from the punitive measures.
Trump’s Tariff Policy Explained
US President Donald Trump announced that from October 1, 2025, all branded and patented drugs imported into the US would attract 100% tariffs unless the manufacturer has started construction of a US-based plant.
This policy aims to force multinational pharma companies to shift production to America. While it disrupts supply chains in Europe and Japan, India’s position remains largely secure due to its focus on generics.
Case Studies: Indian Pharma Majors
Sun Pharmaceutical Industries Ltd.
-
US revenue: $1.9 billion (31% of global revenue at $5.8 billion in FY25).
-
Presence: Subsidiary Taro Pharmaceuticals (listed in the US) and Ohm Laboratories, a manufacturing unit for over-the-counter drugs.
-
Focus: Generics and specialty products — mostly shielded from tariffs.
Dr. Reddy’s Laboratories Ltd.
-
US revenue: $1.73 billion (45% of global revenue at $3.8 billion in FY25).
-
Facilities: Operates an API plant in New York; shut down its Louisiana plant in March 2025.
-
Strategy: Open to expansion in the US, including acquisitions, to sidestep tariffs.
Cipla Ltd.
-
US revenue: $934 million (29% of global revenue at $3.2 billion in FY25).
-
Operations: Subsidiary Cipla USA runs InvaGen Pharmaceuticals in New York and Massachusetts.
-
Portfolio: Respiratory/inhaler generics, branded inhalation drugs, and oncology therapies.
Expert View
Ken Peng, Head of Asia Investment Strategy at Citi Wealth, highlighted that the tariffs largely affect branded finished drugs exported by Europe, Switzerland, and Japan — not the generics supplied by India and China.
This further reinforces that the tariff move has only minimal direct impact on Indian pharma companies.
Conclusion: Minimal Damage, Watchful Future
While the Trump tariff rattled Indian pharma stocks initially, the actual exposure is limited since India mainly supplies generic medicines and maintains a strong manufacturing footprint within the US.
The bigger uncertainty lies in whether complex generics and biosimilars will come under future tariff scrutiny. For now, however, India’s pharma giants remain resilient, backed by their cost-competitive generics model and strategic US operations.

Comments
Post a Comment